The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - First results

被引：0
|
作者：
Van Poznak, C.
Hannon, R. A.
Clack, G.
Campone, M.
Mackeys, J. R.
Apffelstaedt, J.
Eastell, R.
机构：
[1] Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Sheffield, Acad Unit Bone Metabol, Sheffield, S Yorkshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
[4] Site Hosp, Ctr Rene Gauducheau, Nord de Nantes, France
[5] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
[6] Univ Stellenbosch, Dept Surg, Tygerberg, South Africa
来源：
BONE | 2007年 / 40卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [1] First results of the SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer
    Van Poznak, C.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelstaedt, J.
    Eastell, R.
    [J]. CANCER TREATMENT REVIEWS, 2006, 32 : S44 - S44
  • [2] The SABRE (study of anastrozole with the bisphosphonate risedronate) study: The effects of risedronate on BMD and bone metabolism in postmenopausal women using anastrozole as adjuvant therapy for hormone receptor-positive early breast cancer - First results.
    Van Poznak, C.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelstaedt, J.
    Eastell, R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S191 - S192
  • [3] First results of the SABRE study: The effects of risedronate sodium on bone metabolism in postmenopausal women receiving adjuvant anastrozole for early breast cancer
    Eastell, R.
    Hannon, R. A.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelstaed, J. P.
    Van Poznak, C.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S124 - S124
  • [4] A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
    Fiona M. McCaig
    Lorna Renshaw
    Linda Williams
    Oliver Young
    Juliette Murray
    Elizabeth J. Macaskill
    Mary McHugh
    Rosemary Hannon
    J. Michael Dixon
    [J]. Breast Cancer Research and Treatment, 2010, 119 : 643 - 651
  • [5] A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
    McCaig, Fiona M.
    Renshaw, Lorna
    Williams, Linda
    Young, Oliver
    Murray, Juliette
    Macaskill, Elizabeth J.
    McHugh, Mary
    Hannon, Rosemary
    Dixon, J. Michael
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) : 643 - 651
  • [6] Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE)
    Van Poznak, C.
    Hannon, R.
    Clack, G.
    Campone, M.
    Mackey, J. R.
    Apffelsfaedt, J.
    Eastell, R.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 147S - 147S
  • [7] Fulvestrant plus anastrozole as neoadjuvant therapy in postmenopausal women with hormone receptor positive early breast cancer
    Khan, Q. J.
    Barr, J. A.
    Britt, A. S.
    Kimler, B. F.
    Connor, C. S.
    McGinness, M.
    Mammen, J. M. V.
    Wagner, J. L.
    Amin, A.
    Springer, M.
    Baccaray, S.
    Fabian, C. J.
    Sing, A. P.
    Sharma, P.
    [J]. CANCER RESEARCH, 2016, 76
  • [8] Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer
    Sendur, M. A. N.
    Aksoy, S.
    Zengin, N.
    Altundag, K.
    [J]. JOURNAL OF BUON, 2013, 18 (04): : 838 - 844
  • [9] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    [J]. Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
  • [10] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
12345